AAPL352.45+0.54 (+0.15%) ▲|ABBV286.01-6.81 (-2.33%) ▼|ABT105.01+0.30 (+0.29%) ▲|ACN229.79-9.50 (-3.97%) ▼|ADBE227.33-8.23 (-3.49%) ▼|AMAT350.42+1.19 (+0.34%) ▲|AMD521.56+18.15 (+3.61%) ▲|AMGN444.81-13.12 (-2.87%) ▼|AMT185.48+2.30 (+1.26%) ▲|AMZN266.14+8.25 (+3.20%) ▲|AVGO354.80+13.20 (+3.86%) ▲|AXP315.34-0.44 (-0.14%) ▼|BA163.04-0.88 (-0.53%) ▼|BAC48.87-0.57 (-1.15%) ▼|BKNG153.49-0.97 (-0.63%) ▼|BLK1,175.71-4.96 (-0.42%) ▼|BMY60.03-1.32 (-2.15%) ▼|BNY148.47-1.32 (-0.88%) ▼|BRK-B574.32-12.44 (-2.12%) ▼|C117.68-2.26 (-1.88%) ▼|CAT558.37-12.42 (-2.18%) ▼|CL98.99-0.63 (-0.63%) ▼|CMCSA25.34+0.03 (+0.13%) ▲|COF184.29-2.49 (-1.33%) ▼|COP134.94-4.54 (-3.25%) ▼|COST1,103.82-6.26 (-0.56%) ▼|CRM189.64-4.88 (-2.51%) ▼|CSCO96.40+1.29 (+1.36%) ▲|CVS81.63-4.19 (-4.88%) ▼|CVX206.32-8.04 (-3.75%) ▼|DE646.41-2.82 (-0.43%) ▼|DHR228.52+2.75 (+1.22%) ▲|DIS123.08+6.14 (+5.25%) ▲|DUK130.32+0.48 (+0.37%) ▲|EMR162.15+3.00 (+1.89%) ▲|FDX318.25-1.69 (-0.53%) ▼|GD350.16-5.47 (-1.54%) ▼|GE328.02+1.62 (+0.50%) ▲|GEV773.03-6.88 (-0.88%) ▼|GILD169.49-0.77 (-0.45%) ▼|GM82.32-1.74 (-2.06%) ▼|GOOG280.82+3.22 (+1.16%) ▲|GOOGL283.55+3.35 (+1.20%) ▲|GS872.39-5.13 (-0.58%) ▼|HD338.95-0.06 (-0.02%) ▼|HON223.64+4.68 (+2.14%) ▲|IBM228.94-2.15 (-0.93%) ▼|INTC54.21-0.96 (-1.74%) ▼|INTU313.92-6.87 (-2.14%) ▼|ISRG424.57-5.97 (-1.39%) ▼|JNJ273.89-4.81 (-1.73%) ▼|JPM324.76-5.21 (-1.58%) ▼|KO98.15-0.65 (-0.65%) ▼|LIN511.59-3.52 (-0.68%) ▼|LLY1,387.50-28.05 (-1.98%) ▼|LMT578.89-11.45 (-1.94%) ▼|LOW221.94+1.48 (+0.67%) ▲|LRCX209.92-0.77 (-0.37%) ▼|MA644.08-1.65 (-0.26%) ▼|MCD274.06-1.77 (-0.64%) ▼|MDLZ66.76+0.01 (+0.02%) ▲|MDT101.08-1.24 (-1.21%) ▼|META614.60-4.27 (-0.69%) ▼|MMM181.32+0.44 (+0.24%) ▲|MO76.53-0.94 (-1.21%) ▼|MRK138.35-5.02 (-3.50%) ▼|MS180.88-2.65 (-1.44%) ▼|MSFT506.69+0.45 (+0.09%) ▲|MU697.30-15.13 (-2.12%) ▼|NEE84.79+0.37 (+0.43%) ▲|NFLX59.77+0.09 (+0.14%) ▲|NKE36.38+0.53 (+1.48%) ▲|NOW90.65-2.25 (-2.42%) ▼|NVDA150.83-4.63 (-2.98%) ▼|ORCL114.33-0.67 (-0.58%) ▼|PEP141.89-0.13 (-0.09%) ▼|PFE28.13-0.34 (-1.19%) ▼|PG170.66-1.07 (-0.62%) ▼|PLTR156.26-0.31 (-0.19%) ▼|PM193.21-1.17 (-0.60%) ▼|QCOM159.09-7.58 (-4.55%) ▼|RTX197.51-0.49 (-0.25%) ▼|SBUX109.15+1.66 (+1.54%) ▲|SCHW92.40+0.56 (+0.61%) ▲|SO94.52+0.92 (+0.98%) ▲|SPG231.84+1.60 (+0.69%) ▲|T22.01-0.28 (-1.27%) ▼|TMO691.98+5.19 (+0.76%) ▲|TMUS163.36-4.54 (-2.70%) ▼|TSLA382.86+2.75 (+0.72%) ▲|TXN290.67-5.20 (-1.76%) ▼|UBER69.15+0.34 (+0.49%) ▲|UNH347.60-42.08 (-10.80%) ▼|UNP301.61+4.58 (+1.54%) ▲|UPS111.30+0.99 (+0.90%) ▲|USB58.38-0.81 (-1.36%) ▼|V415.48-1.29 (-0.31%) ▼|VZ45.99+0.06 (+0.12%) ▲|WFC81.17-1.52 (-1.84%) ▼|WMT127.13-0.39 (-0.31%) ▼|XOM160.95-6.26 (-3.74%) ▼|AAPL352.45+0.54 (+0.15%) ▲|ABBV286.01-6.81 (-2.33%) ▼|ABT105.01+0.30 (+0.29%) ▲|ACN229.79-9.50 (-3.97%) ▼|ADBE227.33-8.23 (-3.49%) ▼|AMAT350.42+1.19 (+0.34%) ▲|AMD521.56+18.15 (+3.61%) ▲|AMGN444.81-13.12 (-2.87%) ▼|AMT185.48+2.30 (+1.26%) ▲|AMZN266.14+8.25 (+3.20%) ▲|AVGO354.80+13.20 (+3.86%) ▲|AXP315.34-0.44 (-0.14%) ▼|BA163.04-0.88 (-0.53%) ▼|BAC48.87-0.57 (-1.15%) ▼|BKNG153.49-0.97 (-0.63%) ▼|BLK1,175.71-4.96 (-0.42%) ▼|BMY60.03-1.32 (-2.15%) ▼|BNY148.47-1.32 (-0.88%) ▼|BRK-B574.32-12.44 (-2.12%) ▼|C117.68-2.26 (-1.88%) ▼|CAT558.37-12.42 (-2.18%) ▼|CL98.99-0.63 (-0.63%) ▼|CMCSA25.34+0.03 (+0.13%) ▲|COF184.29-2.49 (-1.33%) ▼|COP134.94-4.54 (-3.25%) ▼|COST1,103.82-6.26 (-0.56%) ▼|CRM189.64-4.88 (-2.51%) ▼|CSCO96.40+1.29 (+1.36%) ▲|CVS81.63-4.19 (-4.88%) ▼|CVX206.32-8.04 (-3.75%) ▼|DE646.41-2.82 (-0.43%) ▼|DHR228.52+2.75 (+1.22%) ▲|DIS123.08+6.14 (+5.25%) ▲|DUK130.32+0.48 (+0.37%) ▲|EMR162.15+3.00 (+1.89%) ▲|FDX318.25-1.69 (-0.53%) ▼|GD350.16-5.47 (-1.54%) ▼|GE328.02+1.62 (+0.50%) ▲|GEV773.03-6.88 (-0.88%) ▼|GILD169.49-0.77 (-0.45%) ▼|GM82.32-1.74 (-2.06%) ▼|GOOG280.82+3.22 (+1.16%) ▲|GOOGL283.55+3.35 (+1.20%) ▲|GS872.39-5.13 (-0.58%) ▼|HD338.95-0.06 (-0.02%) ▼|HON223.64+4.68 (+2.14%) ▲|IBM228.94-2.15 (-0.93%) ▼|INTC54.21-0.96 (-1.74%) ▼|INTU313.92-6.87 (-2.14%) ▼|ISRG424.57-5.97 (-1.39%) ▼|JNJ273.89-4.81 (-1.73%) ▼|JPM324.76-5.21 (-1.58%) ▼|KO98.15-0.65 (-0.65%) ▼|LIN511.59-3.52 (-0.68%) ▼|LLY1,387.50-28.05 (-1.98%) ▼|LMT578.89-11.45 (-1.94%) ▼|LOW221.94+1.48 (+0.67%) ▲|LRCX209.92-0.77 (-0.37%) ▼|MA644.08-1.65 (-0.26%) ▼|MCD274.06-1.77 (-0.64%) ▼|MDLZ66.76+0.01 (+0.02%) ▲|MDT101.08-1.24 (-1.21%) ▼|META614.60-4.27 (-0.69%) ▼|MMM181.32+0.44 (+0.24%) ▲|MO76.53-0.94 (-1.21%) ▼|MRK138.35-5.02 (-3.50%) ▼|MS180.88-2.65 (-1.44%) ▼|MSFT506.69+0.45 (+0.09%) ▲|MU697.30-15.13 (-2.12%) ▼|NEE84.79+0.37 (+0.43%) ▲|NFLX59.77+0.09 (+0.14%) ▲|NKE36.38+0.53 (+1.48%) ▲|NOW90.65-2.25 (-2.42%) ▼|NVDA150.83-4.63 (-2.98%) ▼|ORCL114.33-0.67 (-0.58%) ▼|PEP141.89-0.13 (-0.09%) ▼|PFE28.13-0.34 (-1.19%) ▼|PG170.66-1.07 (-0.62%) ▼|PLTR156.26-0.31 (-0.19%) ▼|PM193.21-1.17 (-0.60%) ▼|QCOM159.09-7.58 (-4.55%) ▼|RTX197.51-0.49 (-0.25%) ▼|SBUX109.15+1.66 (+1.54%) ▲|SCHW92.40+0.56 (+0.61%) ▲|SO94.52+0.92 (+0.98%) ▲|SPG231.84+1.60 (+0.69%) ▲|T22.01-0.28 (-1.27%) ▼|TMO691.98+5.19 (+0.76%) ▲|TMUS163.36-4.54 (-2.70%) ▼|TSLA382.86+2.75 (+0.72%) ▲|TXN290.67-5.20 (-1.76%) ▼|UBER69.15+0.34 (+0.49%) ▲|UNH347.60-42.08 (-10.80%) ▼|UNP301.61+4.58 (+1.54%) ▲|UPS111.30+0.99 (+0.90%) ▲|USB58.38-0.81 (-1.36%) ▼|V415.48-1.29 (-0.31%) ▼|VZ45.99+0.06 (+0.12%) ▲|WFC81.17-1.52 (-1.84%) ▼|WMT127.13-0.39 (-0.31%) ▼|XOM160.95-6.26 (-3.74%) ▼|
16 C
New York
Wednesday, November 18, 2026

Tag: 1

Bronstein, Gewirtz & Grossman LLC Urges ZoomInfo Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for ZoomInfo (GTM) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/24/2026

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

University of Phoenix Launches Three New Artificial Intelligence Professional Development Pathways

New offerings help employees, senior leaders and healthcare professionals build practical AI skills for workplace application, governance and healthcare settingsPHOENIX, June 26, 2026 /PRNewswire/...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

FEDERAL-PROVINCIAL-TERRITORIAL MEETING – Ministers Responsible for Canadian Francophonie Review Progress and Future Prospects

WINNIPEG, MB, June 26, 2026 /CNW/ - Under the theme Let's Celebrate the Francophonie at the Heart of Canada, the Ministers' Council on the Canadian Francophonie...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

Free People to Host “Feels Like Free People: A Summer Social” in Philadelphia with Music, Food, and a Cookie Queens Screening

The July 11 event at Marine Parade Grounds will bring together food trucks, lawn games, a DJ set, and a family-friendly documentary screening, with...

EDF: EDF announces the signature of an agreement to sell EDF power solutions in the United States and Canada

EDF announces the signature of an agreement to sell EDF power solutions in the United States and Canada

EDF : EDF annonce la signature d’un accord en vue de céder les activités d’EDF power solutions aux Etats-Unis et au Canada

EDF annonce la signature d’un accord en vue de céder les activités d’EDF power solutions aux Etats-Unis et au Canada

FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health

If finalized, rule would level the playing field between American and foreign businesses
If finalized, rule would level the playing field between American and foreign businesses

TEAMSTERS FORCED ON STRIKE AT OPEN KITCHENS

Company's Unfair Labor Practices Trigger Work Stoppage CHICAGO, June 26, 2026 /PRNewswire/ -- Drivers and helpers at Open Kitchens in Chicago have been forced...

HOFSETH BIOCARE ASA: CONTEMPLATED PRIVATE PLACEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Resultater fra Ultimovacs’ DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan

Oslo, 26. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at den NSGO-CTU sponsede fase II DOVACC kliniske studie (NCT04742075) som testet Ultimovacs' UV1 kreftvaksine ikke oppnådde sitt primære endepunkt om å forbedre progresjonsfri overlevelse (PFS). UV1 ble overtatt gjennom virksomhetssammenslåingen mellom de to selskapene i 2025. Dette avslutter den tidligere kommuniserte avviklingsfasen av UV1-kreftvaksine-programmet, og Zelluna anser nå programmet som avsluttet.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags1